For many people, they provide a jump start when nothing else seems to work
The changes are primarily linked to weight loss rather than a direct effect of the medication itself
Finally, vagal afferents receive metabolic information by chemoreceptors located in the hepatoportal system (Yi et al., 2010
The presence of risk factors does not necessarily contraindicate Zepbound use but should inform shared decision-making and monitoring strategies
TRIUMPH-3: Obesity with Established Cardiovascular Disease (July 2026) TRIUMPH-3 enrolled 1,949 adults with severe obesity (BMI 35) and established cardiovascular disease, with or without type 2 diabetes, randomized 1:1:2 to retatrutide 9mg, 12mg, or placebo over 80 weeks
In the meantime, UK patients with obesity or type 2 diabetes have access to several MHRA-licensed treatments supported by NICE guidance, including: Semaglutide (Wegovy for weight management